Published in final edited form as:

Arthritis Rheumatol. 2016 May ; 68(5): 1057–1059. doi:10.1002/art.39566.

HLA-B27: The Story Continues to Unfold

Simon J. Powis, PhD¹ and Robert A. Colbert, MD, PhD²

¹School of Medicine, University of St Andrews, Scotland, UK, KY16 9TF

²Pediatric Translational Research Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, MD, 20892

The strong association between HLA-B27 and spondyloarthritis, in particular ankylosing spondylitis (AS), was first recognized over forty years ago. Since then a series of hypotheses, based initially on the canonical function of HLA-B27 and more recently on its aberrant behavior, have been proposed to explain its role in disease. While progress has been made, the precise role (or roles) of HLA-B27 in spondyloarthritis remains unclear (1). In the meantime, genome-wide association studies have implicated over 30 genes or genetic regions outside of the major histocompatibility complex (MHC) involved in susceptibility to AS (2). Together with animal models and translational studies, this has strongly implicated activation of the IL-23/IL-17 axis in disease pathogenesis (3). In addition, the identification of a unique population of enthesal-resident T cells in mice that are exquisitely sensitive to IL-23 may help to explain the spondyloarthritis phenotype (4). Thus, while tumor necrosis factor (TNF)-inhibitors are well-established options for control of active disease symptoms, there is a rationale basis to target additional cytokines and pathways (5, 6).

Teasing out the direct influence of HLA-B27 in disease has had a rather bumpy ride. The concept of ‘arthritogenic’ self peptides that become so by virtue of their resemblance to microbial peptides and trigger autoreactive CD8⁺ T cells, lacks significant experimental support. Moreover, there is clear evidence that CD8⁺ T cells are not required for the development of spondyloarthritis in HLA-B27 transgenic rats. Two concepts emerged from the discovery that HLA-B27 displays aberrant folding/unfolding properties compared with other HLA class I molecules (1, 7). To add complexity to the picture, there are at least two sites in cells where HLA-B27 deviates from the norm. First, in the endoplasmic reticulum (ER) newly made heavy chains are slow to fold, which results in the formation of disulfide-linked dimers. The accumulation of such misfolded proteins may generate ER stress and trigger an unfolded protein response (UPR) and ER-associated degradation (ERAD) pathways in an attempt to resolve the burden on the ER (8). Second, after HLA-B27 reaches the cell surface it tends to unfold resulting in the formation of free heavy chains. While cell-surface free heavy chains are not unique to HLA-B27, it has a propensity to form dimers during endosomal recycling resulting in the expression of aberrant cell surface complexes that can be recognized by leukocyte immunoglobulin-like receptors, most notably KIR3DL2. Interestingly, aberrant folding and unfolding of HLA-B27 have been linked to the IL-23/IL-17 axis through UPR-mediated increases in IL-23 production, and triggering of

CD4⁺ Th17 T cells that express KIR3DL2, respectively. These concepts remain as attractive alternatives to the arthritogenic peptide hypothesis, but the extent to which they account for the role of HLA-B27 in spondyloarthritis remains to be determined. Furthermore, effects of HLA-B27 expression on dendritic cell function promote Th17 development in rats, although the molecular mechanism remains to be elucidated.

'B27' designates a family of HLA-B alleles called subtypes, with over 100 described to date (IMGT/HLA database; <http://www.ebi.ac.uk/ipd/imgt/hla/align.html>). Subtypes generally differ by 1 to 6 or 7 amino acids in the mature protein, while different B alleles might contain 15-30 differences (e.g. HLA-B27 and HLA-B7 differ by approximately 20 amino acids, or 6% of the protein). Most HLA-B27 subtypes are extremely rare, with many reported from single individuals, and thus their relationship with AS cannot be discerned. For some of the most commonly occurring subtypes the picture is somewhat clearer. For example, HLA-B*27:05 (B*27:05) and B*27:04 are strongly associated with AS, whereas B*27:06 is clearly not associated. The relatively rare HLA-B*27:09 allele is either not, or is only weakly associated with AS. These four subtypes differ by only 1-4 amino acids located at positions 77, 114, 116, and 152. Differences at amino acids 77 and 152 do not correlate with disease susceptibility, while differences at positions 114 and 116 located at the base of the peptide-binding groove seem to be more critical. The non-associated subtypes B*27:06 and B*27:09 have either Asp at 114 and Tyr at 116 (B*27:06), or His at 116 (B*27:09), while B*27:05 and B*27:04 both contain His at 114 and Asp at 116. Alterations in these residues can alter the types of peptides that bind, though there is significant overlap in the peptide repertoires of all 4 subtypes. Nevertheless, differential peptide binding has been used to support the notion of arthritogenic peptides, presuming a disease-causing peptide would be bound by B*27:04 and B*27:05 subtypes, but not by B*27:06 and B*27:09. Further refinement of this idea was prompted by elegant structural studies of B*27:05 and B*27:09 bound to a self-peptide derived from the vasoactive intestinal peptide type 1 receptor (sequence RRKWRRLHL) (pVIPR) (9). When bound by B*27:05, pVIPR was displayed in two different conformations with the central section of the peptide partially rotated, altering the potential antigenic surface presented to CD8⁺ T cells. Indeed, cytotoxic T lymphocytes could be generated *in vitro* that differentiated between the two orientations of the same peptide. In contrast, pVIPR bound to B*27:09 was observed in only one conformation, leading to speculation that a dual conformation peptide might generate autoreactivity.

In this issue of *Arthritis & Rheumatology*, Loll *et al.* have extended their analysis of HLA-B27 subtypes to include x-ray crystal structures of B*27:04 and B*27:06 with the pVIPR peptide. Rather than observing dual peptide conformations with the disease-associated B*27:04 subtype, this time it was observed for the **non-disease-associated** B*27:06. Thus the ability to present the same peptide in two conformations does not correlate with disease susceptibility as originally thought, nor does it require His 114 and Asp 116 in HLA-B27. The story might have ended here, but the authors followed up on their previous observation that B*27:05 was more flexible than B*27:09 (10). In the current study Loll *et al.* again employed a technique called infrared (IR) spectroscopy, but this time to probe the structures of B*27:04 and B*27:06 complexed with peptide and β_2 -microglobulin (β_2m). IR spectroscopy examines dynamic properties of proteins in contrast to the static structures

visualized by x-ray crystallography. The protein in solution is excited with IR energy and its response is examined. As with B*27:05 and B*27:09, there was a clear delineation between B*27:04 and B*27:06. Furthermore, as with the previous study, the disease associated subtype (B*27:04) exhibited a greater conformational flexibility than the non-disease associated allele (B*27:06). Increased conformational flexibility means a less rigid or more floppy structure. Intrinsically disordered proteins also exhibit greater flexibility with IR spectroscopy. Thus, rather than dual conformation peptides suggesting a subtype-specific basis for autoreactivity, the authors propose that greater structural flexibility or floppiness may contribute to disease. The question is how might this occur?

Increased conformational flexibility seems more consistent with models implicating HLA-B27 misfolding or unfolding in the pathogenesis of AS. Indeed, the authors argue that reduced stability of the peptide-binding groove could support increased heavy chain dimerization and/or contribute to the development of ER stress. While the current studies are based on the biophysical properties of HLA class I complexes containing heavy chain, peptide, and β_2m , the results are strikingly reminiscent of experiments showing that newly-synthesized B*27:05 heavy chains are slow to fold and acquire a compact structure *in vivo*, which is associated with prolonged binding of ER chaperones and results in the formation of aberrant disulfide bonds (11-13). Furthermore, recent studies of Jeanty *et al.* showed increased oligomerization and intracellular accumulation of B*27:05 compared to B*27:06 when these heavy chains were transiently overexpressed in cells (14); precisely what one might predict if these two subtypes differ in their folding and/or unfolding properties. Of course conformational flexibility could also be hypothesized to lead to autoreactivity. The consequence of varied structure might be heterogeneous complexes that do not reach the density required for efficient negative selection of self-reactive CD8+ T cells. This would be consistent with B*27:05 and B*27:04 being disease associated, but not B*27:09. This leaves B*27:06 as the outlier since it is not disease associated but should lead to autoreactivity by virtue of dual conformation peptides. The notion that differential dual peptide conformations play a role for B*27:05/B*27:09, but conformational flexibility is the reason that B*27:04 is associated but not B*27:06 is difficult to reconcile.

As alluded to previously, the dichotomous separation of subtypes into disease-associated and non-disease associated may be too rigid for B*27:09. This subtype is relatively rare, discovered and mostly limited to the Sardinian population where it is part of an extended HLA haplotype. Thus, one caveat is that the statistical power to detect and quantify a weak association between B*27:09 and AS or undifferentiated spondyloarthritis, as suggested by numerous case reports is limited.

Ultimately, all HLA-B27 subtypes (and all HLA class I proteins) function as peptide-antigen presenting molecules. Indeed, it is only through the binding of peptides and β_2m that HLA class I heavy chains achieve the stability necessary to function. It then becomes relevant to ask whether the nature of the peptide pool – either quantitative or qualitative differences – might influence the conformational flexibility of HLA-B27 subtypes? It is noteworthy that variants in ER aminopeptidases (ERAP1 and ERAP2) have been implicated in susceptibility to AS (2, 15). ERAP1/2 are important proteases that trim peptides in the ER to optimize their length for binding to HLA class I proteins. Genetic and functional studies suggest that

loss of ERAP1 function is protective, although more recent analyses of ERAP1 allotype pairs raise the possibility of a more complex relationship where either high or low activity could be detrimental (16). In any event, it would not be surprising if certain peptides were better at limiting the conformational flexibility of HLA-B27, thereby promoting its folding and limiting unfolding.

Detailed and careful structural analyses such as those provided by Loll *et al.* provide an important perspective on the biology of HLA-B27 variants that may prove to be relevant to disease pathogenesis. They emphasize the need for further studies probing structural differences, including dynamic processes such as folding and unfolding. Incorporating complex mixtures of peptides generated with varying influence of ERAP1/2 that better mimic the ER environment is a challenge that if met, may provide unprecedented insights into the role of HLA-B27 in spondyloarthritis.

Acknowledgments

Financial Support: This work was supported by the NIAMS Intramural Research Program, Z01 AR041184 (RAC).

References

1. Bowness P. HLA-B27. *Annu Rev Immunol.* 2015; 33:29–48. [PubMed: 25861975]
2. Robinson PC, Brown MA. Genetics of ankylosing spondylitis. *Mol Immunol.* 2014; 57:2–11. [PubMed: 23916070]
3. Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. *Arthritis Rheumatol.* 2014; 66:231–41. [PubMed: 24504793]
4. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- enthesal resident T cells. *Nat Med.* 2012; 18:1069–76. [PubMed: 22772566]
5. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2013
6. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). *Ann Rheum Dis.* 2014; 73:817–23. [PubMed: 24389297]
7. Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G. From HLA-B27 to spondyloarthritis: a journey through the ER. *Immunol Rev.* 2010; 233:181–202. [PubMed: 20193000]
8. Guiliano DB, Fussell H, Lenart I, Tsao E, Nesbeth D, Fletcher AJ, et al. Endoplasmic reticulum degradation-enhancing alpha-mannosidase-like protein 1 targets misfolded HLA-B27 dimers for endoplasmic reticulum-associated degradation. *Arthritis Rheumatol.* 2014; 66:2976–88. [PubMed: 25132672]
9. Hulsmeier M, Fiorillo MT, Bettosini F, Sorrentino R, Saenger W, Ziegler A, et al. Dual, HLA-B27 subtype-dependent conformation of a self-peptide. *J Exp Med.* 2004; 199:271–81. [PubMed: 14734527]
10. Fabian H, Huser H, Loll B, Ziegler A, Naumann D, Uchanska-Ziegler B. HLA-B27 heavy chains distinguished by a micropolymorphism exhibit differential flexibility. *Arthritis Rheum.* 2010; 62:978–87. [PubMed: 20131248]
11. Dangoria NS, DeLay ML, Kingsbury DJ, Mear JP, Uchanska-Ziegler B, Ziegler A, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. *J Biol Chem.* 2002; 277:23459–68. [PubMed: 11978783]

12. Antoniou AN, Ford S, Taurog JD, Butcher GW, Powis SJ. Formation of HLA-B27 homodimers and their relationship to assembly kinetics. *J Biol Chem.* 2004; 279:8895–902. [PubMed: 14684742]
13. Turner MJ, Sowders DP, DeLay ML, Mohapatra R, Bai S, Smith JA, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. *J Immunol.* 2005; 175:2438–48. [PubMed: 16081815]
14. Jeanty C, Sourisce A, Noteuil A, Jah N, Wielgosik A, Fert I, et al. HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis. *Arthritis Rheumatol.* 2014; 66:2113–23. [PubMed: 24692163]
15. Robinson PC, Lau E, Keith P, Lau MC, Thomas GP, Bradbury LA, et al. ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers. *Ann Rheum Dis.* 2015; 74:2092–5. [PubMed: 26088389]
16. Reeves E, Colebatch-Bourn A, Elliott T, Edwards CJ, James E. Functionally distinct ERAP1 allotype combinations distinguish individuals with Ankylosing Spondylitis. *Proc Natl Acad Sci U S A.* 2014; 111:17594–9. [PubMed: 25422414]